Your browser is no longer supported. Please, upgrade your browser.
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E27.81 EPS (ttm)2.77 Insider Own0.10% Shs Outstand2.53B Perf Week0.52%
Market Cap192.25B Forward P/E11.92 EPS next Y6.46 Insider Trans-0.77% Shs Float2.53B Perf Month-0.36%
Income7.03B PEG2.30 EPS next Q1.31 Inst Own75.20% Short Float0.88% Perf Quarter9.50%
Sales48.02B P/S4.00 EPS this Y-28.00% Inst Trans0.38% Short Ratio1.85 Perf Half Y3.54%
Book/sh10.65 P/B7.22 EPS next Y16.96% ROA7.70% Target Price93.02 Perf Year1.68%
Cash/sh- P/C- EPS next 5Y12.07% ROE25.80% 52W Range68.38 - 83.72 Perf YTD-1.37%
Dividend2.60 P/FCF980.89 EPS past 5Y12.20% ROI10.80% 52W High-8.11% Beta0.42
Dividend %3.38% Quick Ratio0.80 Sales past 5Y4.00% Gross Margin67.70% 52W Low12.50% ATR1.07
Employees74000 Current Ratio1.00 Sales Q/Q0.20% Oper. Margin14.60% RSI (14)49.05 Volatility1.37% 1.28%
OptionableYes Debt/Eq1.16 EPS Q/Q-1.00% Profit Margin14.60% Rel Volume0.96 Prev Close78.33
ShortableYes LT Debt/Eq0.89 EarningsJul 29 BMO Payout90.70% Avg Volume12.06M Price76.93
Recom2.10 SMA20-0.92% SMA501.09% SMA2002.51% Volume11,539,151 Change-1.79%
Jul-27-21Resumed Truist Buy $92
May-20-21Downgrade Argus Buy → Hold
Apr-07-21Resumed RBC Capital Mkts Sector Perform $79
Nov-10-20Resumed Bernstein Outperform $95
Sep-29-20Initiated Berenberg Hold $88
Aug-03-20Upgrade Goldman Neutral → Buy $91 → $105
Jun-12-20Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20Initiated Barclays Overweight $93
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Jul-30-21 01:03AM  
Jul-29-21 05:35PM  
02:06PM  
12:30PM  
11:36AM  
11:24AM  
10:26AM  
08:10AM  
08:05AM  
06:49AM  
06:44AM  
06:39AM  
06:37AM  
06:30AM  
03:59AM  
02:49AM  
Jul-28-21 01:51PM  
01:47PM  
08:51AM  
Jul-27-21 02:12PM  
01:34PM  
06:45AM  
06:30AM  
06:30AM  
Jul-26-21 03:59PM  
11:48AM  
Jul-25-21 06:20PM  
04:18AM  
Jul-23-21 01:53PM  
Jul-22-21 05:45PM  
03:11PM  
03:03PM  
02:36PM  
09:45AM  
06:45AM  
Jul-21-21 01:43PM  
11:22AM  
07:14AM  
Jul-20-21 02:51PM  
08:14AM  
06:00AM  
Jul-19-21 02:01PM  
10:08AM  
09:32AM  
06:56AM  
Jul-18-21 09:18AM  
Jul-16-21 05:45PM  
05:15PM  
01:37PM  
12:46PM  
09:30AM  
07:18AM  
Jul-15-21 05:50PM  
02:58PM  
02:34PM  
01:30PM  
Jul-14-21 01:49PM  
Jul-12-21 03:09PM  
10:04AM  
07:52AM  
06:55AM  
06:45AM  
Jul-10-21 09:01AM  
Jul-09-21 05:45PM  
02:22PM  
08:10AM  
02:30AM  
02:24AM  
Jul-08-21 01:57PM  
Jul-07-21 01:46PM  
11:03AM  
07:58AM  
Jul-06-21 02:21PM  
07:20AM  
06:45AM  
Jul-02-21 01:39PM  
12:27PM  
11:22AM  
08:06AM  
07:38AM  
Jul-01-21 05:45PM  
04:05PM  
01:50PM  
10:51AM  
03:43AM  
Jun-30-21 04:00PM  
02:39PM  
02:20PM  
10:03AM  
Jun-29-21 11:30AM  
09:03AM  
08:30AM  
07:40AM  
07:27AM  
06:45AM  
Jun-28-21 02:09PM  
Jun-25-21 03:18PM  
06:00AM  
Jun-24-21 02:00PM  
01:29PM  
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clyburn FrankEVP & Pres ? Human HealthMay 10Option Exercise0.0019,3240113,672May 11 02:41 PM
Clyburn FrankEVP & Pres ? Human HealthMay 10Sale78.3219,3241,513,44094,348May 11 02:41 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 04Option Exercise75.9841731,6845,662May 06 05:04 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise75.981,21292,08836,215May 06 05:02 PM
Litchfield CarolineEVP & CFOMay 04Option Exercise75.981,03978,94320,230May 06 05:01 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 04Option Exercise75.9869452,7302,612May 06 04:48 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise75.981,906144,81895,287May 06 04:40 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 03Option Exercise74.5087565,18835,303May 04 04:50 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 03Option Exercise74.5041230,6945,387May 04 04:55 PM
Li Dean YExecutive VP & President, MRLMay 03Option Exercise74.5075055,87512,111May 04 04:57 PM
Litchfield CarolineEVP & CFOMay 03Option Exercise74.5075055,87519,544May 04 05:01 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 03Option Exercise74.5043732,5562,068May 04 05:04 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 01Option Exercise74.5062246,3391,841May 04 05:04 PM
Litchfield CarolineEVP & CFOMay 01Option Exercise74.5084062,58019,082May 04 05:01 PM
Li Dean YExecutive VP & President, MRLMay 01Option Exercise74.501,03076,73511,715May 04 04:57 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 01Option Exercise74.5056041,7205,167May 04 04:55 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise74.5090167,12434,737May 04 04:50 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale81.42280,00022,797,011411,546Nov 12 04:45 PM
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise75.892,287173,56013,403Nov 03 04:48 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise75.894,574347,1217,624Nov 03 04:44 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise75.892,287173,56083,656Nov 03 04:55 PM
Davis Robert MEVP, Global Svcs & CFOOct 05Option Exercise0.00251,2730422,329Oct 06 04:52 PM
Davis Robert MEVP, Global Svcs & CFOOct 05Sale81.03251,27320,360,325171,056Oct 06 04:52 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 13Sale83.0110,380861,67667,373Aug 17 06:36 PM
Clyburn FrankEVP, Chief Commercial OfficerAug 05Option Exercise0.0018,876099,639Aug 06 04:53 PM
Clyburn FrankEVP, Chief Commercial OfficerAug 05Sale81.5518,8761,539,27480,763Aug 06 04:53 PM